Supplementary Online Content

doi:10.1001/jama.2016.18315

eMethods. Literature Search Strategies
eTable 1. Quality Assessment Criteria
eTable 2. Study Design and Baseline Characteristics of Participants in Included Studies (Key Question 1a)
eTable 3. Study Design and Baseline Characteristics of Participants in Included Studies (Key Question 3)
eTable 4. Study Design and Baseline Characteristics of Participants in Included Studies (Key Question 4a)
eTable 5. Study Design and Baseline Characteristics of Participants in Included Studies (Key Question 5)
eReferences

This supplementary material has been provided by the authors to give readers additional information about their work.
eMethods. Literature Search Strategies

Literature Search Strategies – Systematic Reviews
Database: Ovid MEDLINE(R) without Revisions <1996 to November Week 2 2013>, Ovid MEDLINE(R) Daily Update <November 20, 2013>, Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations <November 20, 2013>
Search Strategy:

1 Pre-Eclampsia/ ()
2 Hypertension, Pregnancy-Induced/ ()
3 Eclampsia/ ()
4 Pregnancy/ ()
5 Hypertension/ ()
6 4 and 5 ()
7 1 or 2 or 3 or 6 ()
8 Mass screening/ ()
9 Biological markers/ ()
10 Ultrasonography, Doppler/ ()
11 "Predictive Value of Tests"/ ()
12 "Sensitivity and Specificity"/ ()
13 Diagnostic errors/ ()
14 Risk factors/ ()
15 Risk assessment/ ()
16 (screen$ or diagnos$ or predict$ or detect$ or risk$).ti. ()
17 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 ()
18 7 and 17 ()
19 Pre-Eclampsia/di ()
20 Hypertension, Pregnancy-Induced/di ()
21 Eclampsia/di ()
22 18 or 19 or 20 or 21 ()
23 preeclamps$.ti,ab. ()
24 eclamp$.ti,ab. ()
25 gestosis.ti,ab. ()
26 ((gestational or pregnan$) adj5 (tox?emi$ or hypertens$)).ti,ab. ()
27 23 or 24 or 25 or 26 ()
28 (screen$ or diagnos$ or predict$ or detect$ or risk$).ti,ab. ()
29 27 and 28 ()
30 limit 29 to ("in data review" or in process or "pubmed not medline") ()
31 22 or 30 ()
32 limit 31 to systematic reviews ()
33 limit 32 to (english language and yr="2009 -Current") ()
34 remove duplicates from 33 ()
Literature Search Strategies – Primary Literature

MEDLINE
Database: Ovid MEDLINE(R) <1946 to March Week 4 2015>, Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations < April 2, 2015>, Ovid MEDLINE(R) Daily Update <April 2, 2015>
Search Strategy:

1 Pre-Eclampsia/ ()
2 Hypertension, Pregnancy-Induced/ ()
3 Eclampsia/ ()
4 Pregnancy/ ()
5 Pregnancy Trimester, First/ ()
6 Pregnancy Trimester, Second/ ()
7 Pregnancy Trimester, Third/ ()
8 Hypertension/ ()
9 (4 or 5 or 6 or 7) and 8 ()
10 (preeclamp$ or pre eclamp$).ti. ()
11 eclamp$.ti. ()
12 gestosis.ti. ()
13 ((gestational or pregnan$) and (tox?emi$ or hypertens$ or blood pressure)).ti. ()
14 1 or 2 or 3 or 9 or 10 or 11 or 12 or 13 ()
15 Blood pressure/ ()
16 Blood pressure determination/ ()
17 Blood pressure monitoring, Ambulatory/ ()
18 Blood pressure monitors/ ()
19 Urinalysis/ ()
20 Uric acid/ ()
21 Proteinuria/ ()
22 Pregnancy Proteins/ ()
23 Uterine Artery/us ()
24 Ultrasonography, Doppler/ ()
25 Creatinine/ur ()
26 Biological Markers/ ()
27 Pregnancy-Associated Plasma Protein-A/ ()
28 ((blood or systolic or diastolic) adj pressure).ti,ab. ()
29 urinalys$.ti,ab. ()
30 (urine adj (measur$ or analy$ or test$ or collect$)).ti,ab. ()
31 uric acid.ti,ab. ()
32 (proteinuria or albuminuria or urine albumin).ti,ab. ()
33 (ultrasound or ultrasonography).ti,ab. ()
34 uterine artery doppler.ti,ab. ()
35 ((biological or serum) adj3 (marker$ or biomarker$)).ti,ab. ()
36 plasma protein a.ti,ab. ()
37 or/15-36 ()
38 Mass screening/ ()

© 2017 American Medical Association. All rights reserved.
screen$.ti,ab. ()
(detect$ or predict$ or identif$).ti. ()
38 or 39 or 40 ()
14 and (37 or 41) ()
clinical trials as topic/ or controlled clinical trials as topic/ or randomized controlled trials as topic/ or meta-analysis as topic/ ()
(clinical trial or controlled clinical trial or meta analysis or randomized controlled trial).pt. ()
Random$.ti,ab. ()
control groups/ or double-blind method/ or single-blind method/ ()
clinical trial$.ti,ab. ()
controlled trial$.ti,ab. ()
meta analy$.ti,ab. ()
epidemiologic studies/ or cohort studies/ or longitudinal studies/ or follow-up studies/ or prospective studies/ or retrospective studies/ ()
cohort$.ti,ab. ()
longitudinal.ti,ab. ()
incidence stud$.ti,ab. ()
retrospective.ti,ab. ()
(follow-up or followup).ti,ab. ()
prospective.ti,ab. ()
43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 ()
42 and 57 ()
limit 58 to (english language and yr="1990 -Current") ()
remove duplicates from 59 ()
Risk/ ()
Risk factors/ ()
Risk assessment/ ()
risk$.ti,ab. ()
multivariable prediction.ti,ab. ()
61 or 62 or 63 or 64 or 65 ()
14 and 66 ()
limit 67 to (english language and yr="1990 -Current") ()
remove duplicates from 68 ()
"Sensitivity and Specificity"/ ()
"Predictive Value of Tests"/ ()
ROC Curve/ ()
False Negative Reactions/ ()
False Positive Reactions/ ()
Diagnostic Errors/ ()
"Reproducibility of Results"/ ()
Reference Values/ ()
Reference Standards/ ()
Observer Variation/ ()
Receiver operat$.ti,ab. ()
ROC curve$.ti,ab. ()
sensitivity, specificity, predictive value, accuracy, false positive, false negative, miss rate, error rate, 70 or 71 or 72 or 73 or 74 or 75 or 76 or 77 or 78 or 79 or 80 or 81 or 82 or 83 or 84 or 85 or 86 or 87 or 88 or 89
42 and 90
limit 91 to (english language and yr="1990 -Current")
remove duplicates from 92
Mortality, Morbidity, Death,
safety, harm, mortality, complication, (death or deaths), (adverse or unintended or negative) adj (effect or event or reaction or outcome), cesarean section, magnesium sulfate, anxiety, stress, psychological, premature birth, hypermagnesemia, (anxiety or anxious), ((psychological or psychosocial or mental) adj (stress or distress or outcome)), (preterm or premature) adj (birth or deliver), misdiagnosis, overdiagnosis, misclassification, ((unnecessary or unneeded) adj3 (treat or induc or monitor)), (increase adj3 monitor), or/94-118
42 and 119
limit 120 to (english language and yr="1990 -Current")
remove duplicates from 121
60 or 69 or 93 or 122
Animal/ not (Animal/ and Human/)
123 not 124

© 2017 American Medical Association. All rights reserved.
PUBMED

Query
Search (((#24) AND publisher[sb]) AND English[Language]) AND ("1990"[Date - Publication] : "3000"[Date - Publication])
Search (#10 AND #23)
Search #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22
Search "multivariable prediction"[tiab]
Search risk*[tiab]
Search "plasma protein a"[tiab]
Search biological marker*[tiab] OR biological biomarker*[tiab] OR serum marker*[tiab] OR serum biomarker*[tiab]
Search "uterine artery doppler"[tiab]
Search (ultrasound[tiab] or ultrasonography[tiab])
Search (proteinuria[tiab] or albuminuria[tiab] or "urine albumin"[tiab])
Search urinalys*[tiab]
Search blood pressure[tiab] OR systolic pressure[tiab] OR diastolic pressure[tiab]
Search (detect*[title] OR predict*[title] OR identif*[title])
Search screen*[tiab]
Search (#8 OR #9)
Search (hypertens*[title] OR blood pressure[title] OR toxemi*[title] OR toxaemi*[title]) AND (gestational[title] OR pregnan*[title])

Cochrane Central Register of Controlled Clinical Trials (CENTRAL)

#1 preeclamp*:ti,ab,kw
#2 (pre-eclampsia or pre-eclamptic):ti,ab,kw
#3 eclamp*:ti,ab,kw
#4 gestosis:ti,ab,kw
#5 #1 OR #2 OR #3 OR #4
#6 hypertension:ti,ab,kw
#7 hypertensive:ti,ab,kw
#8 (toxemi*:ti,ab,kw or toxaemi*:ti,ab,kw)
#9 "blood pressure":ti,ab,kw near/5 (high or elevated or abnormal):ti,ab,kw
#10 #6 or #7 or #8 or #9
#11 "pregnancy":ti,ab,kw
#12 "pregnant":ti,ab,kw
#13 gestational:ti,ab,kw
#14 #11 OR #12 OR #13
#15 #10 AND #14
#16 #5 or #15
#17 screen*:ti,ab,kw

© 2017 American Medical Association. All rights reserved.
#18  (detect* or predict* or identif*):ti
#19  (blood or systolic or diastolic):ti,ab,kw next pressure:ti,ab,kw
#20  urinalys*:ti,ab,kw
#21  urine:ti,ab,kw next (measur* or analy* or test* or collect*):ti,ab,kw
#22  (proteinuria or albuminuria or "urine albumin"):ti,ab,kw
#23  (ultrasound or ultrasonography):ti,ab,kw
#24  "uterine artery doppler":ti,ab,kw
#25  (biological or serum):ti,ab,kw near/3 (marker* or biomarker*):ti,ab,kw
#26  "plasma protein a":ti,ab,kw
#27  risk*:ti,ab,kw
#28  "multivariable prediction":ti,ab,kw
#29  #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28
#30  #16 and #29 Publication Year from 1990 to 2014, in Trials
### eTable 1. Quality Assessment Criteria

<table>
<thead>
<tr>
<th>Study Design</th>
<th>Adapted Quality Criteria</th>
</tr>
</thead>
</table>
| Randomized controlled trials, adapted from the U.S. Preventive Services Task Force methods<sup>1</sup> | Was there valid random assignment?  
Was allocation concealed?  
Was eligibility criteria specified?  
Were groups similar at baseline?  
Were the outcome assessors blinded?  
Was there intervention fidelity?  
Was there adequate adherence to the intervention?  
Were measurements equal, valid and reliable?  
Was there acceptable followup?  
Was there a difference between those who completed the study and those who withdrew?  
Was the handling of missing data appropriate?  
Were the statistical methods acceptable?  
Was there evidence of selective reporting of outcomes? |
| Observational studies (e.g., prospective cohort studies), adapted from the Newcastle-Ottawa Scale (NOS)<sup>2</sup> | Was there representativeness of the exposed cohort?  
Was the non-exposed systematically selected?  
Was the ascertainment of exposure reported?  
Was eligibility criteria specified?  
Comparability of cohorts on the basis of design or analysis?  
Was the outcome of interest not present at baseline?  
Were measurements equal, valid and reliable?  
Were outcome assessors blinded?  
Was followup long enough for the outcome to occur?  
Was there adequate followup of cohorts?  
Was there adjustment for confounders?  
Were the statistical methods acceptable?  
Was the handling of missing data appropriate? |
| Diagnostic accuracy studies, adapted from the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) II instrument<sup>3</sup> | Could the selection of patients have introduced bias?  
Was a consecutive or random sample of patients enrolled?  
Was a case-control design avoided?  
Did the study avoid inappropriate exclusions?  
Could the conduct or interpretation of the index test have introduced bias?  
Was the index test interpreted without knowledge of the reference standard results?  
If a threshold was use, was it pre-specified?  
Was the fidelity of the index test monitored and/or reported?  
Could the conduct or interpretation of the reference standard have introduced bias?  
Was the reference standard interpreted without knowledge of the index test results?  
Was the fidelity of the reference test monitored and/or reported?  
Could the patient flow have introduced bias?  
Was there an appropriate interval between the index test and reference standard?  
Did all patients receive the same reference standard?  
Did all patient complete all tests?  
Were all patients completing both tests included in the analysis? |
| Before-After<sup>4</sup> | Is the post-intervention group representative?  
Is the pre-intervention group representative?  
Are the pre- and post-intervention groups comparable on the basis of design or analysis?  
Was the assessment of outcomes valid?  
Was the assessment of outcomes reliable?  
Was the method of outcome assessment the same for the pre- and post-intervention groups?  
Did the study report the point of time when the intervention occurred?  
Was the intervention clearly described?  
Were the data collected during a similar timeframe? |

Good quality studies generally meet all quality criteria. Fair quality studies do not meet all the criteria but do not have critical limitations that could invalidate study findings. Poor quality studies have a single fatal flaw or multiple important limitations that could invalidate study findings. Critical appraisal of studies using a priori quality criteria are conducted independently by at least two reviewers. Disagreements in final quality assessment are resolved by consensus, and, if needed, consultation with a third independent reviewer.

© 2017 American Medical Association. All rights reserved.
<table>
<thead>
<tr>
<th>Study</th>
<th>Quality(^a)</th>
<th>Country</th>
<th>n</th>
<th>Maternal age, years (range)</th>
<th>Race/Ethnicity, No. (%):</th>
<th>Gestational age, weeks (range)</th>
<th>Chronic HTN, No. (%)</th>
<th>Gestational HTN, No. (%)</th>
<th>Nulliparity, No. (%)</th>
<th>Suspected PE, No. (%)</th>
<th>Inpatient, No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>McDuffie, 1996(^b)</td>
<td>Fair</td>
<td>United States</td>
<td>2764</td>
<td>28.5 (18-39)</td>
<td>White: 1886 (81.0)</td>
<td>8.6 (NR)</td>
<td>NR</td>
<td>NR</td>
<td>1130 (48.5)</td>
<td>NR</td>
<td>NR</td>
</tr>
</tbody>
</table>

\(^a\)Quality assessed using criteria developed by the U.S. Preventive Services Task Force\(^1\)

\(^b\)Compared a reduced number of perinatal visits (nine prenatal visits; N = 1165) to usual care (14 prenatal visits; N = 1163)

**Abbreviations**: HTN = hypertension; No = number; NR = not reported; PE = preeclampsia; RCT = randomized controlled trial
Table 3. Study Design and Baseline Characteristics of Participants in Included Prospective Cohort Study (Key Question 3)

<table>
<thead>
<tr>
<th>Study</th>
<th>Quality</th>
<th>Country</th>
<th>n</th>
<th>Maternal age, years (range)</th>
<th>Race/Ethnicity, No. (%)</th>
<th>Gestational age, weeks (range)</th>
<th>Chronic HTN, No. (%)</th>
<th>Gestational HTN, No. (%)</th>
<th>Nulliparity, No. (%)</th>
<th>Suspected PE, No. (%)</th>
<th>Inpatient, No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Simeone, 2015&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Fair</td>
<td>Spain and Italy</td>
<td>255</td>
<td>33.4 (NR)</td>
<td>White: 191 (74.9) Black: NR Hispanic: NR Asian: NR</td>
<td>NR (NR)</td>
<td>NR</td>
<td>NR</td>
<td>171 (67.1)</td>
<td>NR</td>
<td>NR</td>
</tr>
</tbody>
</table>

<sup>a</sup>Quality assessed using the Newcastle-Ottawa Scale

<sup>b</sup>Compared anxiety levels in women identified as being at high-risk for pre-eclampsia (experimental, N = 120) and women identified as being at low-risk (control, N = 135)

**Abbreviations:** HTN = hypertension; No = number; NR = not reported; PE = preeclampsia

© 2017 American Medical Association. All rights reserved.
<table>
<thead>
<tr>
<th>Study</th>
<th>Quality</th>
<th>Country</th>
<th>n</th>
<th>Maternal age, years (range)</th>
<th>Race/Ethnicity, No. (%)</th>
<th>Gestational age, weeks (range)</th>
<th>Chronic HTN, No. (%)</th>
<th>Gestational HTN, No. (%)</th>
<th>Nulliparity, No. (%)</th>
<th>Significant Proteinuria, No. (%)</th>
<th>Inpatient, No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tun, 2012</td>
<td>Fair</td>
<td>United States</td>
<td>90</td>
<td>29 (19-42)</td>
<td>White: 71 (76.9)</td>
<td>Black: 5 (5.6) Hispanic: 2 (2.2) Asian: 3 (3.3)</td>
<td>33.8 (24.0-39.0)</td>
<td>20 (22.2)</td>
<td>22 (24.4)</td>
<td>41 (45.6)</td>
<td>27 (31.4)</td>
</tr>
<tr>
<td>Stout, 2013</td>
<td>Fair</td>
<td>United States</td>
<td>35</td>
<td>27.1 (26.0-28.6)</td>
<td>White: NR Black: 222 (65.2) Hispanic: NR Asian: NR</td>
<td>31.8 (30.7-32.8)</td>
<td>85 (23.9)</td>
<td>7 (2)</td>
<td>NR</td>
<td>144 (40.4)</td>
<td>334 (93.7)</td>
</tr>
<tr>
<td>Wheeler, 2007</td>
<td>Fair</td>
<td>United States</td>
<td>12</td>
<td>26.6 (NR)</td>
<td>White: 91 (72) Black: 34 (27) Hispanic: 1 (1) Asian: NR</td>
<td>34 (NR)</td>
<td>NR</td>
<td>NR</td>
<td>71 (56)</td>
<td>68 (54.0)</td>
<td>126 (100)</td>
</tr>
<tr>
<td>Young, 1996</td>
<td>Fair</td>
<td>United States</td>
<td>45</td>
<td>NR (NR)</td>
<td>White: NR Black: NR Hispanic: NR Asian: NR</td>
<td>33.4 (NR)</td>
<td>NR</td>
<td>NR</td>
<td>29 (57.8)</td>
<td>NR</td>
<td>45 (100)</td>
</tr>
<tr>
<td>Verdonk, 2014</td>
<td>Good</td>
<td>Netherlands</td>
<td>10</td>
<td>31 (IQR 28-34)</td>
<td>White: NR Black: NR Hispanic: NR Asian: NR</td>
<td>31 (IQR 29-35)</td>
<td>NR</td>
<td>NR</td>
<td>59 (56.2)</td>
<td>73 (69.5)</td>
<td>105 (100)</td>
</tr>
<tr>
<td>Lamontagne, 2014</td>
<td>Good</td>
<td>Canada</td>
<td>91</td>
<td>31.8 (≥ 18)</td>
<td>White: 57 (62.6) Black: 26 (28.6) Hispanic: NR Asian: NR</td>
<td>32.3 (NR)</td>
<td>34 (37.4)</td>
<td>NR</td>
<td>42 (46.2)</td>
<td>43 (47.3)</td>
<td>57 (62.6)</td>
</tr>
<tr>
<td>Study</td>
<td>Qualitya</td>
<td>Country</td>
<td>n</td>
<td>Maternal age, years (range)</td>
<td>Race/Ethnicity, No. (%)</td>
<td>Gestational age, weeks (range)</td>
<td>Chronic HTN, No. (%)</td>
<td>Gestational HTN, No. (%)</td>
<td>Nulliparity, No. (%)</td>
<td>Significant Proteinuria, No. (%)b</td>
<td>Inpatient, No. (%)</td>
</tr>
<tr>
<td>-------</td>
<td>-----------</td>
<td>------------------</td>
<td>---</td>
<td>-----------------------------</td>
<td>-------------------------</td>
<td>-------------------------------</td>
<td>---------------------</td>
<td>------------------------</td>
<td>-------------------</td>
<td>---------------------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>Bhide, 201513</td>
<td>Fair</td>
<td>United Kingdom</td>
<td>11</td>
<td>7</td>
<td>30.8 (NR)</td>
<td>White: NR</td>
<td>Black: NR</td>
<td>Hispanic: NR</td>
<td>Asian: NR</td>
<td>36.1 (21.0-41.0)</td>
<td>NR</td>
</tr>
<tr>
<td>Durnwald, 200314</td>
<td>Fair</td>
<td>United States</td>
<td>22</td>
<td>0</td>
<td>26.1 (NR)</td>
<td>White: NR</td>
<td>Black: 95 (43.2)</td>
<td>Hispanic: NR</td>
<td>Asian: NR</td>
<td>36.5 (NR)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Valdes, 201515</td>
<td>Fair</td>
<td>Chile</td>
<td>72</td>
<td></td>
<td>30.5 (NR)</td>
<td>White: NR</td>
<td>Black: NR</td>
<td>Hispanic: NR</td>
<td>Asian: NR</td>
<td>NR (NR)</td>
<td>72 (100)</td>
</tr>
</tbody>
</table>

Multiple spot urine tests (protein creatinine or albumin creatinine) or dipsticks

<table>
<thead>
<tr>
<th>Study</th>
<th>Qualitya</th>
<th>Country</th>
<th>n</th>
<th>Maternal age, years (range)</th>
<th>Race/Ethnicity, No. (%)</th>
<th>Gestational age, weeks (range)</th>
<th>Chronic HTN, No. (%)</th>
<th>Gestational HTN, No. (%)</th>
<th>Nulliparity, No. (%)</th>
<th>Significant Proteinuria, No. (%)b</th>
<th>Inpatient, No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dwyer, 200816</td>
<td>Good</td>
<td>United States</td>
<td>11</td>
<td>6</td>
<td>30.8 (NR)</td>
<td>White: 47 (40.5)</td>
<td>Black: 14 (12)</td>
<td>Hispanic: 36 (31)</td>
<td>Asian: 19 (16)</td>
<td>NR (NR)</td>
<td>26 (22.4)</td>
</tr>
<tr>
<td>Waugh, 200517</td>
<td>Good</td>
<td>United Kingdom</td>
<td>17</td>
<td>1</td>
<td>29 (19-40)</td>
<td>White: 167 (97.7)</td>
<td>Black: NR</td>
<td>Hispanic: NR</td>
<td>Asian: 4 (2.3)</td>
<td>NR (NR)</td>
<td>NR</td>
</tr>
<tr>
<td>Kyle, 200818</td>
<td>Fair</td>
<td>New Zealand</td>
<td>15</td>
<td>0</td>
<td>NR (NR)</td>
<td>White: 136 (90.7)</td>
<td>Black: NR</td>
<td>Hispanic: NR</td>
<td>Asian: NR</td>
<td>34.0 (20.1-30.7)</td>
<td>19 (12.7)</td>
</tr>
</tbody>
</table>

Protein dipsticks only

<table>
<thead>
<tr>
<th>Study</th>
<th>Qualitya</th>
<th>Country</th>
<th>n</th>
<th>Maternal age, years (range)</th>
<th>Race/Ethnicity, No. (%)</th>
<th>Gestational age, weeks (range)</th>
<th>Chronic HTN, No. (%)</th>
<th>Gestational HTN, No. (%)</th>
<th>Nulliparity, No. (%)</th>
<th>Significant Proteinuria, No. (%)b</th>
<th>Inpatient, No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Waugh, 200119</td>
<td>Fair</td>
<td>United Kingdom</td>
<td>19</td>
<td>7</td>
<td>27 (18.4-38)</td>
<td>White: 171 (86.8)</td>
<td>Black: NR</td>
<td>Hispanic: NR</td>
<td>Asian: NR</td>
<td>36.14 (24.1-39.6)</td>
<td>NR</td>
</tr>
</tbody>
</table>

aQuality assessed using the QUADAS II tool1

bFor Key Question 4a, all pregnant women had suspected pre-eclampsia; the data in this column reflects those with significant proteinuria according to the 24-hour urine collection (reference standard), the definition of significant proteinuria varied across studies

**Abbreviations:** HTN = hypertension; No = number; NR = not reported; PE = preeclampsia

© 2017 American Medical Association. All rights reserved.
Table 5. Study Design and Baseline Characteristics of Participants in Included Before-After Study (Key Question 5)

<table>
<thead>
<tr>
<th>Study</th>
<th>Quality</th>
<th>Country</th>
<th>n</th>
<th>Maternal age, years (range)</th>
<th>Race/Ethnicity, No. (%)</th>
<th>Gestational age, weeks (range)</th>
<th>Chronic HTN, No. (%)</th>
<th>Gestational HTN, No. (%)</th>
<th>Nulliparity, No. (%)</th>
<th>Suspected PE, No. (%)</th>
<th>Inpatient, No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rhode, 2007&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Fair</td>
<td>United States</td>
<td>1952</td>
<td>24.7 (NR)</td>
<td>White: 199 (10.2)</td>
<td>Black: 180 (9.2)</td>
<td>Hispanic: 1472 (74.4)</td>
<td>Asian: NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
</tbody>
</table>

<sup>a</sup>Quality assessed using the Before After Quality Assessment tool<sup>2</sup>

<sup>b</sup>Compared women who were enrolled and delivered prior to August 15, 2002 who underwent routine urine screening (N = 933) to women who were enrolled and delivered on or after August 15, 2002 who underwent indicated urine testing (N = 1019)

**Abbreviations:** HTN = hypertension; No = number; NR = not reported; PE = preeclampsia; RCT = randomized controlled trial
References


